Detailed description of Pretomanid’s domestic launch time, approval status and marketing progress

Pretomanid (Pretomanid) is a new anti-tuberculosis drug mainly used to treat patients with multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). It achieves bactericidal effects by inhibiting Mycobacterium tuberculosis cell wall synthesis and interfering with energy metabolism. According to the current domestic drug registration information, Putomani has not yet been officially launched in China. Therefore, domestic patients cannot obtain the drug through regular hospital pharmacies for the time being, and it is not included in the scope of medical insurance.

In overseas markets, the original drug Putomani has been approved and used for clinical treatment. The common specifications are 200mg*26 tablets per box, and the price per box may be as high as more than 600 US dollars. Due to its strong pertinence and significant curative effect, especially for patients with drug-resistant tuberculosis, putomanid has been gradually promoted and used in Europe, the United States and some developing countries. The higher prices of original drugs also limit their accessibility to some patients, making generic drugs in overseas markets an economically viable alternative.

Overseas generic drugs have been put on the market in many countries, and their drug ingredients are basically the same as the original drugs. For example, the specification produced by a Lao pharmaceutical factory is 200mg*30 tablets. Each box sells for about more than 2,000 yuan (affected by exchange rate fluctuations), which greatly reduces the cost of medication for patients. These generic drugs have undergone strict quality control and clinical verification to provide safe and effective treatment options for patients at home and abroad, especially when the original drugs are too expensive or difficult to obtain.

Overall, Putomani is not yet on the market in China, but there are original drugs and generic drugs available in overseas markets with clear clinical value, and it is mainly used for the treatment of multi-drug-resistant and extensively drug-resistant tuberculosis. In the future, with the advancement of the domestic drug approval process and the development of relevant clinical research, Putomani is expected to enter the domestic market, meet the urgent treatment needs of drug-resistant tuberculosis patients, and provide new drug means for public health prevention and control.

Keyword tag:

Pretomanid, Pretomanid, drug-resistant tuberculosis, MDR-TB, XDR-TB, domestically marketed, overseas original drugs, generic drugs, prices, indications

Reference materials:https://en.wikipedia.org/wiki/Pretomanid